BRAF and melanoma: While our results do not support BRAF mutations to be associated with a poor prognosis in advanced melanoma, as suggested by Long et al. [9], their study reported survival for patients with BRAF-mutated tumors found ineligible for BRAF inhibitor trials who, as stated by the authors, are expected to be a poor-survival group due to intercurrent medical problems [9].